Qaiser Bashir Selected Research

Plasma Cell Leukemia

7/2022	A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial.
7/2021	Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era.
6/2021	Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era.
12/2020	Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era.
1/2019	Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia.
1/2019	Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Qaiser Bashir Research Topics

Disease

42	Multiple Myeloma 07/2022 - 01/2012
18	Neoplasms (Cancer) 01/2022 - 10/2005
15	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2021 - 07/2011
11	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2022 - 11/2010
8	Lymphoma (Lymphomas) 01/2022 - 03/2013
6	Plasma Cell Leukemia 07/2022 - 01/2019
6	Hematologic Neoplasms (Hematological Malignancy) 01/2022 - 02/2014
6	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2021 - 01/2013
5	Residual Neoplasm 01/2020 - 01/2017
4	Chromosome Aberrations (Chromosome Abnormalities) 01/2021 - 02/2013
3	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2021 - 01/2016
3	Mucositis 05/2019 - 01/2016
3	Immunoglobulin Light-chain Amyloidosis 11/2018 - 08/2015
2	Disease Progression 01/2019 - 10/2013
2	Dermatitis 06/2017 - 01/2016
2	Amyloidosis 02/2016 - 02/2011
2	Hodgkin Disease (Hodgkin's Disease) 03/2013 - 11/2012
1	T-Cell Lymphoma (Lymphoma, T Cell) 01/2022
1	COVID-19 12/2021
1	Hemorrhagic Cystitis 01/2021
1	Cytokine Release Syndrome 01/2021
1	cell-associated neurotoxicity 01/2021
1	Hemorrhage 01/2021
1	Thrombocytopenia (Thrombopenia) 01/2021
1	Primary Myelofibrosis (Myelosclerosis) 01/2021
1	Philadelphia Chromosome 10/2020
1	Idiopathic Noncirrhotic Portal Hypertension 01/2020
1	Pathologic Complete Response 01/2020
1	Ascites 01/2020
1	Portal Hypertension 01/2020
1	Waldenstrom Macroglobulinemia (Macroglobulinemia) 09/2019
1	POEMS Syndrome (Syndrome, POEMS) 01/2019
1	Vomiting 01/2018
1	Diarrhea 01/2018
1	Nausea 01/2018
1	Stomatitis 01/2018
1	Congenital Bone Marrow Failure Syndromes 12/2017
1	Inborn Genetic Diseases (Disease, Hereditary) 12/2017
1	Hemoglobinopathies 12/2017
1	Infections 04/2017

Drug/Important Bio-Agent (IBA)

20	Melphalan (Alkeran)FDA LinkGeneric 01/2022 - 01/2012
12	Busulfan (Busulfex)FDA Link 01/2021 - 07/2011
9	fludarabineIBA 01/2021 - 07/2011
8	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2021 - 06/2012
7	Bortezomib (Velcade)FDA Link 01/2022 - 05/2012
7	Lenalidomide (CC 5013)FDA Link 01/2022 - 03/2013
5	Dexamethasone (Maxidex)FDA LinkGeneric 01/2022 - 02/2017
4	Gemcitabine FDA Link 01/2020 - 11/2012
4	Rituximab (Mabthera)FDA Link 01/2019 - 06/2012
3	Tacrolimus (Prograf)FDA LinkGeneric 12/2021 - 11/2016
3	FM 100 (FM100)IBA 01/2019 - 10/2013
3	Immunomodulating AgentsIBA 11/2018 - 09/2017
3	Proteasome InhibitorsIBA 11/2018 - 09/2017
3	DNA (Deoxyribonucleic Acid)IBA 04/2017 - 01/2013
2	ixazomibIBA 07/2022 - 01/2022
2	Mycophenolic Acid (Cellcept)FDA LinkGeneric 12/2021 - 11/2016
2	Alemtuzumab (Campath)FDA Link 01/2020 - 03/2013
2	Antilymphocyte Serum (Anti-Thymocyte Globulin)IBA 01/2020 - 07/2011
2	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2019 - 03/2016
2	Clofarabine (Clolar)FDA Link 02/2017 - 03/2013
2	Amyloid (Amyloid Fibrils)IBA 02/2016 - 02/2011
2	Vorinostat FDA Link 01/2016 - 11/2015
2	AntigensIBA 01/2016 - 01/2016
2	Azacitidine (5 Azacytidine)FDA Link 01/2016 - 01/2013
2	MethyltransferasesIBA 01/2016 - 01/2013
2	HLA Antigens (Human Leukocyte Antigens)IBA 12/2014 - 11/2010
1	SteroidsIBA 01/2022
1	carboxyl radical (COO-)IBA 01/2021
1	eltrombopag FDA Link 01/2021
1	Chimeric Antigen ReceptorsIBA 01/2021
1	Methotrexate (Mexate)FDA LinkGeneric 01/2021
1	CytokinesIBA 01/2021
1	GlucocorticoidsIBA 11/2020
1	Monoclonal AntibodiesIBA 05/2020
1	venetoclaxIBA 01/2020
1	PanobinostatIBA 01/2020
1	AlbuminsIBA 01/2020
1	Core Binding Factors (Core-Binding Factor)IBA 01/2020
1	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2019
1	Etoposide (VP 16)FDA LinkGeneric 01/2019
1	Carmustine (FIVB)FDA Link 01/2019
1	HLA-DPB1 antigen (HLA DPB1)IBA 01/2019
1	Amifostine (Ethyol)FDA LinkGeneric 01/2018
1	Transaminases (Aminotransferases)IBA 06/2017
1	Tenofovir (Viread)FDA Link 04/2017
1	Lamivudine (Epivir)FDA Link 04/2017

Therapy/Procedure

30	Hematopoietic Stem Cell Transplantation 01/2022 - 12/2011
24	Cell Transplantation 07/2022 - 07/2011
24	Stem Cell Transplantation 01/2022 - 12/2011
22	Therapeutics 07/2022 - 10/2005
18	Transplantation 01/2022 - 07/2011
14	Drug Therapy (Chemotherapy) 01/2020 - 07/2012
6	Homologous Transplantation 07/2022 - 06/2012
5	Autologous Transplantation 01/2021 - 02/2017
3	Haploidentical Transplantation 12/2019 - 01/2018
1	Immunotherapy 01/2021
1	Retreatment 01/2021
1	Catheters 01/2020
1	BEAM regimen 01/2019
1	Isogeneic Transplantation 01/2018